Clay Siegall, the chief executive officer of Immunome, Inc., made a notable investment by purchasing 7,278 shares of the company’s stock on December 19, 2023. The acquisition at an average price of $20.48 per share resulted in a total transaction value of $149,053.44. Following this purchase, Siegall now holds 860,525 shares of Immunome, which are currently valued at approximately $17.6 million.
This recent transaction reflects a 0.85% increase in Siegall’s ownership position, showcasing confidence in the company’s future. The details of the acquisition were made public in a filing with the Securities and Exchange Commission.
Stock Performance and Market Overview
On the morning of December 22, 2023, shares of Immunome opened at $21.44. The stock has demonstrated significant volatility over the past year, with a low of $5.15 and a high of $25.30. Currently, the stock boasts a market capitalization of $1.97 billion, a price-to-earnings ratio of -7.27, and a beta of 2.17, indicating higher volatility compared to the market as a whole.
Immunome recently reported its earnings results for the third quarter on November 6, 2023, revealing an earnings per share (EPS) of ($0.65), which missed analysts’ consensus estimate of ($0.57) by ($0.08). The company experienced a negative net margin of 1,687.08% and a negative return on equity of 76.50%. Analysts project that Immunome will report an EPS of ($2.21) for the current fiscal year.
Analyst Ratings and Market Sentiment
Recent analyst evaluations have shown a mixed sentiment regarding Immunome’s stock. On November 22, 2023, Wall Street Zen upgraded the stock from a “sell” rating to a “hold” rating. In contrast, Craig Hallum initiated coverage on September 5, 2023, assigning a “buy” rating with a price target of $26.00. Following suit, Lake Street Capital raised their target price from $22.00 to $32.00, while maintaining a “buy” rating in a report dated December 16, 2023.
Additionally, The Goldman Sachs Group initiated coverage on September 22, 2023, issuing a “buy” rating with a price target of $26.00. Truist Financial also entered the scene with a “buy” rating and a price target of $36.00 on December 1, 2023. Currently, ten analysts have rated the stock as a “buy,” while one has assigned a “sell” rating, resulting in a consensus rating of “Moderate Buy” with an average price target of $30.09.
Immunome, Inc. is recognized as a clinical-stage biotechnology company dedicated to discovering and developing innovative antibody-based therapeutics aimed at treating oncology and infectious diseases. The company utilizes its proprietary platform to mine the natural B-cell repertoire of patients with active disease, allowing for the identification of fully human monoclonal antibodies with unique mechanisms of action. Immunome’s lead oncology program, IMM-BCP-01, is currently undergoing early-stage clinical trials targeting breast cancer antigens.
As the market continues to evolve, the performance of Immunome and the strategic decisions made by its leadership, including recent stock purchases, will be closely monitored by investors and analysts alike.
